Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee.
Panebianco V, Briganti A, Efstathiou J, Galgano S, Luk L, Muglia VF, Redd B, de Rooij M, Takeuchi M, Woo S, Witjes JA, Vargas HA. Panebianco V, et al. Among authors: briganti a. Eur Urol. 2024 Dec;86(6):485-487. doi: 10.1016/j.eururo.2024.09.013. Epub 2024 Sep 23. Eur Urol. 2024. PMID: 39317635
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, Da Pozzo LF, Picchio M, Di Girolamo V, Salonia A, Gianolli L, Messa C, Rigatti P, Montorsi F. Briganti A, et al. Eur Urol. 2010 Apr;57(4):551-8. doi: 10.1016/j.eururo.2009.12.023. Epub 2009 Dec 18. Eur Urol. 2010. PMID: 20034730
Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F. Colombo R, et al. Among authors: briganti a. Eur Urol. 2012 Nov;62(5):797-802. doi: 10.1016/j.eururo.2012.05.032. Epub 2012 May 18. Eur Urol. 2012. PMID: 22633362 Clinical Trial.
Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.
Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A. Abdollah F, et al. Among authors: briganti a. Eur Urol. 2013 Oct;64(4):557-64. doi: 10.1016/j.eururo.2013.03.006. Epub 2013 Mar 13. Eur Urol. 2013. PMID: 23506833
Survivorship and improving quality of life in men with prostate cancer.
Bourke L, Boorjian SA, Briganti A, Klotz L, Mucci L, Resnick MJ, Rosario DJ, Skolarus TA, Penson DF. Bourke L, et al. Among authors: briganti a. Eur Urol. 2015 Sep;68(3):374-83. doi: 10.1016/j.eururo.2015.04.023. Epub 2015 May 1. Eur Urol. 2015. PMID: 25941049 Review.
1,603 results